Published Articles

Solid Lipid Nanoparticles: Drug Delivery Technology September 2009 Vol 9 No 8. Solid Lipid Nanoparticles for the Delivery of Pharmaceutical Actives.

An increasing number of active pharmaceutical ingredients (APIs) under development are poorly water soluble and therefore have poor bioavailability. These are designated Biopharmaceutical Classification System (BCS) class II and class IV APIs.1-3 Creative formulation efforts are required to produce a finished drug product from these APIs that has acceptable pharmacokinetics. A common formulation approach with such compounds is to focus on creating and stabilizing very small particles of the API in an attempt to increase the surface area available for dissolution in vivo, and hence the rate of dissolution, and consequently plasma or tissue levels of API. Another approach is to create so-called solid solutions of the API.4.

Read the full article here.